Top Page
Icecure Medical
(NASDAQ:ICCM)
Icecure Medical (ICCM) vs. SPDR S&P 500 ETF (SPY)
Icecure Medical Business Overview & Revenue Model
Icecure Medical Earnings Call Summary
Icecure Medical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.98M | 3.29M | 3.23M | 3.08M | 4.14M | 4.08M |
| Gross Profit | 1.04M | 1.45M | 1.30M | 1.45M | 2.19M | 2.66M |
| EBITDA | -15.10M | -15.36M | -15.25M | -16.49M | -9.60M | -4.08M |
| Net Income | -15.29M | -15.32M | -14.65M | -17.22M | -10.07M | ― |
Balance Sheet | ||||||
| Total Assets | 15.08M | 12.58M | 16.41M | 30.19M | 32.28M | 10.34M |
| Cash, Cash Equivalents and Short-Term Investments | 10.01M | 7.56M | 11.06M | 23.66M | 25.62M | 3.50M |
| Total Debt | 288.00K | 459.00K | 599.00K | 597.00K | 909.00K | 301.04K |
| Total Liabilities | 5.77M | 5.67M | 4.25M | 4.77M | 5.32M | 5.75M |
| Stockholders Equity | 9.31M | 6.90M | 12.16M | 25.42M | 26.96M | 4.58M |
Cash Flow | ||||||
| Free Cash Flow | -13.79M | -12.63M | -13.00M | -15.18M | -13.14M | -3.91M |
| Operating Cash Flow | -13.75M | -12.56M | -12.52M | -14.29M | -12.61M | -3.69M |
| Investing Cash Flow | -5.04M | 446.00K | -713.00K | -891.00K | 3.79M | -4.67M |
| Financing Cash Flow | 13.21M | 9.19M | 83.00K | 13.58M | 30.89M | 5.86M |
Icecure Medical Technical Analysis
Icecure Medical Risk Analysis
Icecure Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $82.08M | -1.38 | -73.73% | ― | 15.59% | 4.13% | |
50 Neutral | $45.00M | -11.39 | -91.34% | ― | 250.35% | 83.06% | |
45 Neutral | $46.13M | -2.57 | -157.91% | ― | -18.96% | 8.98% | |
44 Neutral | $44.04M | -3.84 | -96.15% | ― | -8.97% | 47.29% | |
44 Neutral | $47.20M | -1.21 | ― | ― | 12.24% | 47.45% | |
41 Neutral | $48.49M | -2.12 | ― | ― | -15.02% | -11.06% |
Icecure Medical Corporate Events
On January 12, 2026, IceCure Medical reported that 2025 was a pivotal year marked by FDA marketing authorization in October 2025 for its ProSense® cryoablation system as the only on-label, minimally invasive device for the local treatment of low-risk breast cancer in women aged 70 and older with endocrine therapy, including non-surgical candidates, opening access to an estimated 200,000 U.S. patients annually. Following this clearance, the company experienced strong demand in the U.S. and record European sales, leading to preliminary record ProSense® sales of about $3.4 million and cash and cash equivalents of approximately $8.9 million for the year ended December 31, 2025, alongside record scientific visibility via independent peer-reviewed studies and conference presentations covering breast, musculoskeletal, kidney, lung cancers and endometriosis, as well as regulatory approvals in Switzerland and Israel and expansion of its patent portfolio, underscoring its strengthened commercial and clinical positioning in the global cryoablation market.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.71 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On January 8, 2026, IceCure Medical Ltd. signed a first amendment to its equity distribution agreement with Maxim Group LLC, extending the termination date of the arrangement from January 13, 2026, to March 13, 2026. The amendment preserves the company’s ability to offer and sell up to $13,960,500 of its ordinary shares through Maxim over this extended period, effectively giving IceCure additional flexibility and time to tap the at-the-market equity program as a financing tool within the existing $13.96 million capacity.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On January 7, 2026, IceCure Medical held a Special General Meeting of Shareholders in which a quorum was present and investors approved all agenda items outlined in a previously distributed proxy statement. Following the vote, amendments to the company’s Amended and Restated Articles of Association took effect immediately, formally updating its corporate governance framework, including provisions on share capital, shareholder rights, board structure and officer protections, and reinforcing its positioning as a U.S.-listed foreign private issuer by defining federal district courts as the exclusive U.S. forum for certain securities-related claims, with implications for how shareholders may pursue legal actions and how the company manages regulatory and governance obligations across jurisdictions.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
IceCure Medical announced its expectation to achieve record-breaking North American sales in the fourth quarter of 2025, boosted by the recent FDA approval of ProSense® for treating low-risk breast cancer in women aged 70 and above. The FDA authorization in October 2025 has led to a surge in demand, with influential U.S. hospital networks adopting the technology, underscoring the growing preference for minimally invasive cancer therapies and potentially expanding its market reach.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On December 10, 2025, IceCure Medical announced that its ProSense® Cryoablation technology was featured in four independent studies presented at the Radiological Society of North America’s Annual Meeting, held from November 30 to December 4, 2025. These studies, involving 263 patients, highlight the growing adoption and effectiveness of ProSense® in treating breast cancer, particularly as a non-surgical option for patients not suitable for surgery. The presentation of these studies at such a prestigious global platform underscores the increasing recognition of IceCure’s technology within the medical community, following recent FDA marketing approval for low-risk breast cancer treatment.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On December 5, 2025, IceCure Medical announced it received a Notice of Allowance for a patent in China for its Cryogen Flow Control, enhancing the efficacy and precision of its cryoablation procedures. This development strengthens IceCure’s intellectual property portfolio, which now includes 55 patents worldwide, and supports its strategic positioning as a leader in cryoablation technology, particularly following the FDA marketing authorization for its ProSense® system in treating low-risk breast cancer.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
IceCure Medical Ltd. has announced a Special General Meeting of Shareholders scheduled for January 7, 2026, where shareholders will vote on key proposals including updates to the compensation of the CEO and Chairman, and amendments to the company’s Articles of Association. The meeting is significant for stakeholders as it involves decisions that could impact the company’s governance and executive compensation structure.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On November 19, 2025, IceCure Medical reported its financial and operational results for the nine months ending September 30, 2025. A significant development was the FDA’s marketing authorization in October 2025 for the ProSense® cryoablation system, targeting low-risk breast cancer in women aged 70 and above. This milestone is expected to drive demand and commercial momentum in the U.S. and globally. The company anticipates an increase in ProSense® installations and procedure volumes, with regulatory approvals expanding in markets like Switzerland. Despite a slight revenue decline, IceCure is optimistic about future growth, supported by new clinical studies and regulatory milestones.
The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On November 18, 2025, IceCure Medical announced that its ProSense® Cryoablation System received regulatory approval from Swissmedic for treating breast, lung, liver, and kidney cancers in Switzerland. This approval enhances IceCure’s regulatory and commercial momentum, following the recent FDA marketing authorization for low-risk breast cancer in the U.S. The Swiss healthcare market, known for its innovation and high-quality care, offers significant potential for IceCure to expand the adoption of ProSense® as a standard-of-care alternative to surgery, further solidifying its position in the global medical technology industry.
The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On November 14, 2025, IceCure Medical Ltd. announced it received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days, until May 11, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. The notice does not immediately affect the company’s Nasdaq listing, and IceCure is considering options to address the deficiency if necessary, to maintain its listing status.
The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On November 5, 2025, IceCure Medical announced the promotion of Shay Levav to Chief Operating Officer as the company prepares for increased commercial activity following the FDA’s marketing clearance of its ProSense® system for low-risk breast cancer. Mr. Levav, who has been with the company since 2020, will continue to oversee Regulatory Affairs, Quality Assurance, and Clinical Affairs. This strategic move is expected to enhance IceCure’s operational effectiveness and strengthen its market presence in the U.S., as the company anticipates growing demand for its innovative cryoablation technology.
The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On November 3, 2025, IceCure Medical announced the successful results of an independent study published in PLOS One, demonstrating the effectiveness of its Cryoablation System combined with stereotactic body radiation therapy (SBRT) in treating stage I non-small cell lung cancer (NSCLC) with tumors ≥2 cm. The study, which involved 64 patients, showed a 92% disease-specific 5-year survival rate and a 74% overall survival rate, significantly higher than SBRT alone. These findings suggest that IceCure’s technology could provide a minimally invasive treatment option for inoperable NSCLC patients, potentially impacting major markets like the U.S. and Europe.
The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
On October 16, 2025, IceCure Medical Ltd. announced the termination of Ms. Galit Malik, the Vice President of Operations and Services, effective January 15, 2026. The company clarified that the termination was not due to any disagreements related to its operations, policies, or practices. This move could potentially impact the company’s operational dynamics, although no immediate implications for stakeholders were mentioned.
The most recent analyst rating on (ICCM) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.